Product Data Sheet

Product Name: TT-OAD2
Cat. No.: GC70629

Chemical Properties

Cas. No.	2382719-60-8		
Formula	$C_{50}H_{49}Cl_4N_3O_6$	M.Wt	929.75
Solubility	DMSO : 110 mg/mL (118.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)	Storage	4°C, sealed storage, away from moisture and light
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			



Background

TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment.

TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-

arrestin responses in a concentration-dependent manner in HEK293A cells[1].

TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1].

References:
[1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.
[2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.